Skip to main content
Log in

Regulation of leukotriene biosynthesis

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Leukotrienes are products of arachidonic acid metabolism derived through the action of the 5-lipoxygenase enzyme pathway. Leukotriene B4 has been implicated as a mediator of inflammation through induction of leukocyte and lymphocyte activation. The cysteinyl leukotrienes are important mediators of immediate hypersensitivity reactions and initiate smooth muscle contraction. Regulation of the production of leukotrienes can be achieved either through the action of direct 5-lipoxygenase inhibitors or indirect leukotriene biosynthesis inhibitors which bind to 5-lipoxygenase activating protein. Leukotriene C4 synthase and leukotriene A4 hydrolase represent alternative enzymic targets within the biosynthetic cascade. Leukotriene receptor antagonists also have important therapeutic possibilities and in particular, leukotriene D4 receptor antagonists have shown utility in the treatment of human bronchial asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ford-Hutchinson AW: Activation of the 5-lipoxygenase pathway of arachidonic acid metabolism. In: Chung KF, Barnes PJ (eds) Pharmacology of the Respiratory Tract: Clinical and Experimental. Marcel Dekker, New York, 1993, pp 375–414

    Google Scholar 

  2. Snyder DW, Fleisch JH: Leukotriene receptor antagonists as potential therapeutic agents. Annu Rev Pharmacol Toxicol 29: 123–143, 1989

    Google Scholar 

  3. Piper PJ: Leukotrienes: potent mediators of airway constriction. Int Arch Allergy Appl Immunol 76 (Suppl 1): 43–48, 1985

    Google Scholar 

  4. Bel EH, van der Veen H, Kramps JA, Dijkman JH, Sterk PJ: Maximal airway narrowing to inhaled leukotriene D4 in normal subjects, comparison and interaction with methacholine. Am Rev Respir Dis 136: 979–984, 1987

    Google Scholar 

  5. Arm JP, Spur BW, Lee TH: The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 82: 654–660, 1988

    Google Scholar 

  6. O'Hickey SP, Hawksworth RJ, Fong CY, Arm JP, Spur BW, Lee TH: Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 144: 1053–1057, 1991

    Google Scholar 

  7. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286: 264–265, 1980

    Google Scholar 

  8. Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT: Inhibition of leukotriene (LT) D4-induced bronchoconstriction in asthmatic subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis 141: A33, 1990

    Google Scholar 

  9. Goetzl EJ, Pickett WC: The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). J Immunol 125: 1789–1791, 1980

    Google Scholar 

  10. Rae SA, Smith MJH: The stimulation of lysosomal enzyme secretion from human polymorphonuclear leucocytes by leukotriene B4. J Pharm Pharmacol 33: 616–617, 1981

    Google Scholar 

  11. Serhan CN, Radin A, Smolen JE, Korchak H, Samuelsson B, Weissmann G: Leukotriene B4 is a complete secretagogue in human neutrophils: a kinetic analysis. Biochem Biophys Res Commun 107: 1006–1012, 1982

    Google Scholar 

  12. Hoover RL, Karnovsky MJ, Austen KF, Corey EJ, Lewis RA: Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci USA 81: 2192–2193, 1984

    Google Scholar 

  13. Dahlén S-E, Björk J, Hedqvist P, Arfors K-E, Hammarström S, Lindgren J-Å, Samuelsson B: Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules:in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 78: 3887–3891, 1981

    Google Scholar 

  14. Bray MA, Ford-Hutchinson AW, Smith MJH: Leukotriene B4: an inflammatory mediatoryin vivo. Prostaglandins 22: 213–222, 1981b

    Google Scholar 

  15. Lehr HA, Guhlmann A, Nolte D, Keppler D, Messmer K: Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster. J Clin Invest 87: 2036–2041, 1991

    Google Scholar 

  16. Jutila MA, Rott L, Berg EL, Butcher EC: Function and regulation of the neutrophil MEL-14 antigenin vivo: comparison with LFA-1 and Mac-1. J Immunol 143: 3318–3324, 1984

    Google Scholar 

  17. Kishimoto TK, Jutila MA, Berg EL, Butcher EC: Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 245: 1238–1241, 1989

    Google Scholar 

  18. Ford-Hutchinson AW: Leukotriene B4 in inflammation. Crit Rev Immunol 10: 1–12, 1990

    Google Scholar 

  19. Bray MA, Cunningham FM, Ford-Hutchinson AW, Smith MJH: Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol 72: 483–486, 1981

    Google Scholar 

  20. Wedmore CV, Williams TJ: Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 289: 646–650, 1981

    Google Scholar 

  21. Rackham A, Ford-Hutchinson AW: Inflammation and pain sensitivity: effects of leukotrienes D4, B4 and prostaglandin E1 in the rat paw. Prostaglandins 25: 193–203, 1983

    Google Scholar 

  22. Levine JD, Gooding J, Donatoni P, Borden L, Goetzl EJ: The role of the polymorphonuclear leukocyte in hyperalgesia. J Neurosci 5: 3025–3029, 1985

    Google Scholar 

  23. Levine JD, Lau W, Kwiat G, Goetzl EJ: Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 225: 743–745, 1984

    Google Scholar 

  24. Dugas B, Paul-Eugene N, Cairns J, Gordon J, Calenda A, Mencia-Huerta JM, Braquet P: Leukotriene B4 potentiates the expression and release of FCεRII/CD23, and proliferation and differentiation of human B lymphocytes induced by IL-4. J Immunol 145: 3406–3411, 1990

    Google Scholar 

  25. Yamaoka KA, Claésson H-E, Rosén A: Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. J Immunol 143: 1996–2000, 1989

    Google Scholar 

  26. Goldman DW, Goetzl EJ: Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes. J Immunol 129: 1600–1604, 1982

    Google Scholar 

  27. Goldman DW, Goetzl EJ: Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B4: Identification of a subset of high affinity receptors that transduce the chemotactic response. J Exp Med 159: 1027–1041, 1984

    Google Scholar 

  28. Ford-Hutchinson AW, Charleson S, Evans JF: Leukotriene B4 receptors on rat and human neutrophil membranes. Methods Enzymol 163: 340–343, 1988

    Google Scholar 

  29. Payan DG, Missirian-Bastian A, Goetzl EJ: Human T-lymphocyte subset specificity of the regulatory effects of leukotriene B4. Proc Natl Acad Sci USA 81: 3501–3505, 1984

    Google Scholar 

  30. Ford-Hutchinson AW, Gresser M, Young RN: 5-Lipoxygenase. Annu Rev Biochem 63: 338–417, 1994

    Google Scholar 

  31. Batt DG: 5-Lipoxygenase inhibitors and their anti-inflammatory activities. Prog Med Chem 29: 1–63, 1992

    Google Scholar 

  32. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, Brooks DW: 5-Lipoxygenase inhibitory activity of zileuton. J Pharm Exp Ther 256: 929–937, 1991

    Google Scholar 

  33. Crawley DC, Dowell RI, Edwards PN, Foster SJ, McMillan RM: Methoxytetrahydropyrans, a new series of selective and orally potent 5-lipoxygenase inhibitors. J Med Chem 35: 2600–2609, 1992

    Google Scholar 

  34. Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, Piechuta H, Riendeau D, Rouzer CA, Rokach J, Young R, MacIntyre DE, Peterson L, Bach T, Eiermann G, Hopple S, Humes J, Hupe L, Luell S, Metzger J, Meurer R, Miller DK, Opas E, Pacholok S: L-663,536 (MK-886)(3-[1-(4-chloro benzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 67: 456–464, 1989

    Google Scholar 

  35. Rouzer CA, Rands E, Kargman S, Jones RE, Register RB, Dixon RAF: Characterization of cloned human leukocyte 5-lipoxygenase expressed in mammalian cells. J Biol Chem 263: 10135–10140, 1988

    Google Scholar 

  36. Rouzer CA, Ford-Hutchinson AW, Morton HE, Gillard JW: MK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 265: 1436–1442, 1990

    Google Scholar 

  37. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Léveillé C, Mancini JA, Charleson P, Dixon RAF, Ford-Hutchinson AW, Fortin R, Gauthier J-Y, Rodkey J, Rosen R, Rouzer C, Sigal IS, Strader CD, Evans JF: Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343: 278–281, 1990

    Google Scholar 

  38. Dixon RAF, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343: 282–284, 1990

    Google Scholar 

  39. Coffey M, Peters-Golden M, Fantone JC III, Sporn PHS: Membrane association of active 5-lipoxygenase in resting cells. J Biol Chem 267: 570–576, 1992

    Google Scholar 

  40. Kargman S, Vickers PJ, Evans JF: A23187 induced translocation of 5-lipoxygenase in osteoscarcoma cells. J Cell Biol 119: 1701–1709, 1992

    Google Scholar 

  41. Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ: 5-lipoxygenase activating protein is an arachidonate binding protein. FEBS Lett 318: 277–281, 1993

    Google Scholar 

  42. Hill E, Maclouf J, Murphy RC, Henson PM: Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention activity and a change in substrate specificity. J Biol Chem 267: 22048–22053, 1992

    Google Scholar 

  43. Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RAF: Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). J Biol Chem 266: 8511–8516, 1991

    Google Scholar 

  44. Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibein JA, Charleson S, Singer I: 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 178: 1935–1946, 1993

    Google Scholar 

  45. Charleson S, Evans JF, Zamboni RJ, Leblanc Y, Fitzsimmons BJ, Léveillé C, Dupuis P, Ford-Hutchinson AW: Leukotriene B3, leukotriene B4, and leukotriene B5; binding to leukotriene B4 receptors on rat and human leukocyte membranes. Prostaglandins 32: 503–516, 1986

    Google Scholar 

  46. Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D, Hutchinson JH, Jones TR, Leger S, Mancini JA, McFarlane CS, Pickett C, Piechuta H, Prasit P, Riendeau D, Rouzer CA, Tagaro P, Vickers PJ, Young RN, Abraham WM: Pharmacology of MK-591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 70: 799–807, 1992

    Google Scholar 

  47. Nicholson DW, Ali A, Klemba MK, Munday NA, Zamboni RJ, Ford-Hutchinson AW: Human leukotriene C4 synthase expression in dimethylsulfoxide-differentiated U937 cells. J Biol Chem 267: 17849–17857, 1992

    Google Scholar 

  48. Nicholson DN, Klemba MW, Rasper DM, Metters KM, Zamboni RJ, Ford-Hutchinson AW: Purification of leukotriene C4 synthase from dimethylsulfoxide-differentiated U937 cells. Eur J Biochem 209: 725–734, 1992

    Google Scholar 

  49. Nicholson DW, Ali A, Vaillancourt JP, Calaycay JR, Mumford RA, Zamboni RJ, Ford-Hutchinson AW: Purification to homogeneity and N-terminal sequence of human leukotriene C4 synthase: a homodimeric glutathione S-transferase comprised of 18-kDa subunits. Proc Natl Acad Sci USA 90: 2015–2019, 1993

    Google Scholar 

  50. Ali A, Zamboni RJ, Ford-Hutchinson AW, Nicholson DW: Photoaffinity labelling of human leukotriene C4 synthase in THP-1 cell membranes. FEBS Lett 317: 195–201, 1993

    Google Scholar 

  51. Kargman S, Ali A, Vaillancourt JP, Evans JF, Nicholson DW: Protein kinase C dependent regulation of sulfidopeptide leukotriene biosynthesis and leukotriene C4 synthase in neutrophil HL-60 cells. Mol Pharmacol, in press

  52. Radmark O, Shimizu T, Jörnvall H, Samuelsson B: Leukotriene A4 hydrolase in human leukocytes. Purification and properties. J Biol Chem 259: 12339–12345, 1984

    Google Scholar 

  53. Evans JF, Dupuis P, Ford-Hutchinson AW: Purification and characterization of leukotriene A4 hydrolase from rat neutrophils. Biochim Biophys Acta 840: 43–50, 1985

    Google Scholar 

  54. McGee J, Fitzpatrick F: Enzymatic hydration of leukotriene A4. Purification and characterization of a novel epoxide hydrolase from human erythrocytes. J Biol Chem 260: 12832–12837, 1985

    Google Scholar 

  55. Evans JF, Nathaniel DJ, Zamboni RJ, Ford-Hutchinson AW: Leukotriene A3. A poor substrate but a potent inhibitor of rat and human neutrophil leukotriene A4 hydrolase. J Biol Chem 260: 10966–10970, 1985

    Google Scholar 

  56. Minami M, Ohno S, Kawasaki H, Rádmark O, Samuelsson B, Jörnvall H, Shimizu T, Seyama Y, Suzuki K: Molecular cloning of a cDNA coding for human leukotriene A4 hydrolase: complete primary structures of an enzyme involved in eicosanoid synthesis. J Biol Chem 262: 13873–13876, 1987

    Google Scholar 

  57. Örning L, Hammerström S: Inhibition of leukotriene C and leukotriene D biosynthesis. J Biol Chem 255: 8023–8026, 1980

    Google Scholar 

  58. Medina JF, Wetterholm A, Rádmark O, Shapiro R, Haeggström JZ, Vallee BL, Samuelsson B: Leukotriene A4 hydrolase: determination of the three zinc-binding ligands by sitedirected mutagenesis and zinc analysis. Proc Natl Acad Sci USA 88: 7620–7624, 1991

    Google Scholar 

  59. Yan W, Wong C-H, Haeggström JZ, Wetterholm A, Samuelsson B: Novel tight-binding inhibitors of leukotriene A4 hydrolase. J Am Chem Soc 114: 6552–6553, 1992

    Google Scholar 

  60. Augstein J, Farmer JB, Lee TB, Sheard P, Tattersall ML: Selective inhibitor of slow reacting substance of anaphylaxis. Nature, New Biol 245: 215–217, 1973

    Google Scholar 

  61. Fleisch JH, Rinkema LE, Haisch KP, Swanson-Bean D, Goodson T, Ho PPK, Marshall WS: LY171,883, 1-[2—hydroxy-3-propyl-4[4-(1H-tetrazol-5-yl)butoxyphenyl]-ethanone, an orally active leukotriene D4 antagonist. J Pharmacol Exp Ther 233: 148–157, 1985

    Google Scholar 

  62. Jones TR, Young R, Champion E, Charette L, Denis D, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Guindon Y, Kakushima M, Masson P, McFarlane C, Piechuta H, Rokach J, Zamboni R, DeHaven RN, Maycock A, Pong SS: L-649,923, sodium (βS⋆,σR⋆)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-σ-hydroxy-β-methylbenzene-butanoate, elective, orally active leukotriene receptor antagonist. Can. J. Physiol. Pharmacol. 64: 1068–1075, 1986b

    Google Scholar 

  63. Jones TR, Guindon Y, Young R, Champion E, Charette L, Denis D, Ethier D, Hamel R, Ford-Hutchinson AW, Fortin R, Letts G, Masson P, McFarlane C, Piechuta H, Rokach J, Yoakim C, DeHaven RN, Maycock A, Pong SS: L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl sulfonyl]-γ-oxo-benzenebutanoate: a leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 64: 1535–1542, 1986a

    Google Scholar 

  64. Tomioka K, Yamada T, Mase T, Hara H, Murase K: Pharmacological properties of the orally active leukotriene antagonist [[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetic acid. Arzneimittelforschung 38: 682–685, 1988

    Google Scholar 

  65. Hay DWP, Muccitelli RM, Tucker SS, Vickery-Clark LM, Wilson KA, Gleason JG, Hall RF, Wasserman MA, Torphy TJ: Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther 243: 474–481, 1987

    Google Scholar 

  66. Van Inwegen RG, Nuss GW, Carnathan GW: Antagonism of peptidoleukotrienes and inhibition of systemic anaphylaxis by RG 12525 in guinea pigs. Life Sci 44: 799–807, 1989

    Google Scholar 

  67. Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Leger S, Masson P, McFarlane CS, Piechuta H, Rokach J, Williams H, Young RN, DeHaven RN, Pong SS: Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 67: 17–28, 1989

    Google Scholar 

  68. Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Gauthier J-Y, Leger S, Lord A, Masson P, McFarlane CS, Metters KM, Pickett C, Piechuta H, Young RN: Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can J Physiol Pharmacol 69: 1847–1854, 1991

    Google Scholar 

  69. Ford-Hutchinson AW: Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions. In: MacDonald SM (ed.) IgE Immunopathology II (Springer Seminars in Immunopathology; 15) Springer-Verlag, Berlin, 1993, pp 37–50

    Google Scholar 

  70. Krell RD, Aharony D, Buckner CK, Keith RA, Kusner EJ, Snyder DW,Bernstein PR, Matassa VG, Yee YK, Brown FJ, Hesp B, Giles RE: The preclinical pharmacology of ICI-204219: a peptide leukotriene antagonist. Am Rev Respir Dis 141: 978–987, 1990

    Google Scholar 

  71. Namiki M, Igarashi Y, Sakamoto K, Nakamura T, Koga Y: Pharmacological profiles of a potential LTB4-antagonist, SM-9064. Biochem Biophys Res Commun 138: 540–546, 1986

    Google Scholar 

  72. Richards IM, Griffin RL, Oostveen JA, Morris J, Wishka DG, Dunn CJ: Effect of selective leukotriene B4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs. Am Rev Respir Dis 140: 1712–1716, 1989

    Google Scholar 

  73. Djuric SW, Collins PW, Jones PH, Shone RL, Tsai BS, Fretland DJ, Butchko GM, Villani-Price D, Keith RH, Zemaitis JM, Metcalf L, Bauer RF: 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist. J Med Chem 32: 1145–1147, 1989

    Google Scholar 

  74. Wickremasinghe RG, Khan MA, Hoffbrand AV: Do leukotrienes play a role in the regulation of proliferation of normal and leukemic hemopoietic cells? Prostaglandins Leukot Essent Fatty Acids 48: 123–126, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ford-Hutchinson, A.W. Regulation of leukotriene biosynthesis. Cancer Metast Rev 13, 257–267 (1994). https://doi.org/10.1007/BF00666096

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666096

Key words

Navigation